Cartesian Therapeutics Inc’s filing revealed that its Director SPRINGER TIMOTHY A acquired Company’s shares for reported $0.51 million on Apr 10 ’25. In the deal valued at $10.47 per share,48,595 shares were bought. As a result of this transaction, SPRINGER TIMOTHY A now holds 620,175 shares worth roughly $5.68 million.
Then, SPRINGER TIMOTHY A bought 41,782 shares, generating $393,947 in total proceeds. Upon buying the shares at $9.43, the Director now owns 571,580 shares.
Before that, SPRINGER TIMOTHY A bought 36,338 shares. Cartesian Therapeutics Inc shares valued at $391,455 were divested by the Director at a price of $10.77 per share. As a result of the transaction, SPRINGER TIMOTHY A now holds 656,513 shares, worth roughly $6.01 million.
BTIG Research initiated its Cartesian Therapeutics Inc [RNAC] rating to a Buy in a research note published on December 19, 2024; the price target was $42. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Oppenheimer also remained covering RNAC and has decreased its forecast on July 02, 2024 with a “Perform” recommendation from previously “an Outperform” rating. Oppenheimer started covering the stock on June 04, 2024. It rated RNAC as “an Outperform”.
Price Performance Review of RNAC
On Friday, Cartesian Therapeutics Inc [NASDAQ:RNAC] saw its stock jump 0.16% to $9.16. Over the last five days, the stock has lost -10.72%. Cartesian Therapeutics Inc shares have fallen nearly -48.86% since the year began. Nevertheless, the stocks have fallen -62.76% over the past one year. While a 52-week high of $41.87 was reached on 01/16/25, a 52-week low of $8.85 was recorded on 04/09/25. SMA at 50 days reached $11.96, while 200 days put it at $16.72.
Levels Of Support And Resistance For RNAC Stock
The 24-hour chart illustrates a support level at 8.99, which if violated will result in even more drops to 8.82. On the upside, there is a resistance level at 9.34. A further resistance level may holdings at 9.53. The Relative Strength Index (RSI) on the 14-day chart is 35.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.84, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.42%. Stochastics %K at 1.91% indicates the stock is a buying.
How much short interest is there in Cartesian Therapeutics Inc?
A steep rise in short interest was recorded in Cartesian Therapeutics Inc stocks on 2025-04-30, growing by 0.44 million shares to a total of 2.53 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 2.1 million shares. There was a rise of 17.25%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 24, 2024 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
